Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
March 21, 2019
Athenex Announces Expansion of Board of Directors
BUFFALO, N.Y., March 21, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for ...
March 21, 2019
Athenex Announces Xiangxue Life Sciences Receives IND Allowance from China’s National Medical Products Administration for Cancer Immunotherapy Drug Candidate
BUFFALO, N.Y., March 21, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for ...
March 20, 2019
Actinium Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Highlights
NEW YORK, March 19, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) reported its financial results for the fourth quarter and year ended December 31, ...
March 20, 2019
PolarityTE to Present at Oppenheimer 29th Annual Healthcare Conference
SALT LAKE CITY, March 19, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE) announced today that it will attend and present at the Oppenheimer 29th Annual Healthcare Conference on ...
March 20, 2019
Actinium Appoints Accomplished FDA and Industry Professional Mamata Gokhale, Ph.D., RAC as Vice President, Global Head of Regulatory Affairs
NEW YORK, March 19, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced today the appointment of Mamata Gokhale, Ph.D., RAC as Vice President, ...
March 20, 2019
2018 financial results and business update: landmark deal with AstraZeneca to support transition into a fully integrated oncology-focused biotech, strong clinical progress in lead assets
Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) today reports its consolidated financial results for the year ended December 31, 2018. The consolidated ...
March 20, 2019
Alexion and Zealand Pharma Announce Collaboration to Discover and Develop Peptide Therapies for Complement-Mediated Diseases
BOSTON & COPENHAGEN, Denmark, March 20, 2019 - Alexion Pharmaceuticals, Inc. (ALXN) and Zealand Pharma A/S (ZEAL) today announced a collaboration to discover and develop ...
March 20, 2019
Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019
PALO ALTO, Calif., March 20, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare ...
March 20, 2019
Actinium Announces Update Including IP and New Data from Novel Combination of Actimab-A and Venetoclax Accepted for Poster Presentation at AACR Annual Meeting
NEW YORK, March 20, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced today that preclinical data from the novel combination of its CD33 ARC ...
March 20, 2019
Aptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory Diseases
SEATTLE, March 20, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, announced today ...
March 20, 2019
Quantum Genomics Announces Positive Results from New Preclinical Studies on Firibastat
PARIS and NEW YORK, March 20, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company announces positive results from preclinical ...
March 19, 2019
iCAD Reports Fourth Quarter and Full-Year 2018 Financial Results
NASHUA, N.H. , March 18, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today ...
March 19, 2019
Celyad’s 2019 R&D Day Highlights shRNA Platform and Pipeline of Next-generation NKG2D-based and Off-the-Shelf Non-gene Edited CAR-T Candidates
MONT-SAINT-GUIBERT, Belgium, March 18, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of ...
March 19, 2019
Celyad’s 2019 R&D Day Highlights shRNA Platform and Pipeline of Next-generation NKG2D-based and Off-the-Shelf Non-gene Edited CAR-T Candidates
MONT-SAINT-GUIBERT, Belgium, March 18, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of ...
March 19, 2019
CohBar Reports Fourth Quarter 2018 Financial Results and Provides Business Update
MENLO PARK, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related ...
March 19, 2019
Pfenex to Present at the 29th Annual Oppenheimer & Co. Healthcare Conference
SAN DIEGO, March 18, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex ...
March 19, 2019
Opiant Pharmaceuticals to Report Fiscal 2018 Financial Results and Host Conference Call and Webcast on Thursday, March 21
SANTA MONICA, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, ...
March 19, 2019
electroCore to Announce Fourth Quarter and Year Ended December 31, 2018 Financial Results on Wednesday, March 27
BASKING RIDGE, N.J., March 18, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced that it will report fourth quarter ...
March 19, 2019
aTyr Pharma to Announce Fourth Quarter and Full Year 2018 Financial Results on March 25th
SAN DIEGO, March 18, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based ...
March 19, 2019
Immutep to Present IMP761 Preclinical Results in Global Webcast
SYDNEY, Australia, March 18, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments ...
Page 5 of 138